Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

NASDAQ:AURA

Aura Biosciences, Inc.

Last Close

10.96

08/11 21:00

Market Cap

367.12M

Beta: -

Volume Today

114.63K

Avg: 116.01K

PE Ratio

−3.16

PFCF: −5.86

People Not Available